Patricia Vaughn-Goodman, APRN
Family · Ninety Six, SCNPI 1669466074
Payments from drug & device makers
Across 82 payments — averaging $16.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$253
- Pfizer$169
- AstraZeneca$135
- Novo Nordisk$111
- Amgen$96
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$60
- plus $499 from 16 others
What the payments were for
- Food & beverage$1,323100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 16 | $253 |
| Pfizer | 14 | $169 |
| AstraZeneca | 9 | $135 |
| Novo Nordisk | 7 | $111 |
| Amgen | 5 | $96 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $60 |
| Exact Sciences | 3 | $53 |
| Sumitomo Pharma America, Inc. | 2 | $52 |
| GSK | 3 | $50 |
| Peerless Surgical Inc. | 1 | $48 |
| Boehringer Ingelheim | 3 | $43 |
| AbbVie | 1 | $31 |
| Tolmar, Inc. | 2 | $30 |
| Corcept Therapeutics | 2 | $28 |
| Phathom Pharmaceuticals, Inc. | 2 | $27 |
| Antares Pharma, Inc. | 2 | $27 |
| Globus Medical | 1 | $21 |
| Merck | 1 | $19 |
| Edwards Lifesciences | 1 | $18 |
| Organon | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$1,323 in reported general payments places this provider in the 70th percentile of 3,248 family providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 51 | $41,174 |
| JardianceEmpagliflozin | 35 | $37,635 |
| OzempicSemaglutide | 20 | $27,964 |
| TrulicityDulaglutide | 33 | $27,259 |
| JanuviaSitagliptin Phosphate | 16 | $19,094 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $13,855 |
| FarxigaDapagliflozin Propanediol | 15 | $9,329 |
| Esomeprazole Magnesium | 23 | $5,316 |
| Pregabalin | 52 | $4,410 |
| Rosuvastatin Calcium | 219 | $4,067 |
| Atorvastatin Calcium | 195 | $4,027 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $4,021 |
| Omeprazole | 215 | $3,766 |
| Duloxetine Hcl | 78 | $3,763 |
| VascepaIcosapent Ethyl | 11 | $3,669 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $169 | $41,17451 claims |
| Boehringer IngelheimJardiance | $43 | $37,63535 claims |
| Novo NordiskOzempic | $111 | $27,96420 claims |
| Lilly USA, LLCTrulicity | $253 | $27,25933 claims |
| MerckJanuvia | $19 | $19,09416 claims |
| GSKTrelegy Ellipta | $50 | $13,85512 claims |
| AstraZenecaFarxiga | $135 | $9,32915 claims |
| AbbVieSynthroid | $31 | $1,13019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,248 family providers in South Carolina.
Other family in Ninety Six
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Kara Cooper GilmerAnderson$127K
- Jessica BellEasley$96K
- Carrie HendersonGreenville$91K
- Sarah ValerioGreer$76K
- Mary WilliamsColumbia$67K
- Michelle StrongGreenville$55K
- Karen McKerihanSummerville$54K
- Doris ReidSimpsonville$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.